Analyst Scoreboard: 5 Ratings For Integra Lifesciences

5 analysts have expressed a variety of opinions on Integra Lifesciences IART over the past quarter, offering a diverse set of opinions from bullish to bearish.

The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.

In the assessment of 12-month price targets, analysts unveil insights for Integra Lifesciences, presenting an average target of $48.6, a high estimate of $55.00, and a low estimate of $44.00. This upward trend is evident, with the current average reflecting a 9.21% increase from the previous average price target of $44.50.

Deciphering Analyst Ratings: An In-Depth Analysis

The analysis of recent analyst actions sheds light on the perception of Integra Lifesciences by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Integra Lifesciences. This offers insight into analysts' perspectives on the current state of the company.
• Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Integra Lifesciences compared to the broader market.
• Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Integra Lifesciences's stock. This comparison reveals trends in analysts' expectations over time.

Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Integra Lifesciences's market position. Stay informed and make well-informed decisions with our Ratings Table.

Stay up to date on Integra Lifesciences analyst ratings.

All You Need to Know About Integra Lifesciences

Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and tissue technologies. Codman specialty surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales.

Unraveling the Financial Story of Integra Lifesciences

Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.

Revenue Challenges: Integra Lifesciences's revenue growth over 3 months faced difficulties. As of 30 September, 2023, the company experienced a decline of approximately -0.72%. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.

Net Margin: Integra Lifesciences's net margin excels beyond industry benchmarks, reaching 5.1%. This signifies efficient cost management and strong financial health.

Return on Equity (ROE): Integra Lifesciences's ROE excels beyond industry benchmarks, reaching 1.2%. This signifies robust financial management and efficient use of shareholder equity capital.

Return on Assets (ROA): Integra Lifesciences's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 0.52%, the company showcases efficient use of assets and strong financial health.

Debt Management: With a high debt-to-equity ratio of 1.07, Integra Lifesciences faces challenges in effectively managing its debt levels, indicating potential financial strain.

How Are Analyst Ratings Determined?

Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.

Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.

This article was generated by Benzinga's automated content engine and reviewed by an editor.